http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018202140-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_764c37797762f79bedf08832dbf3a65a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_927cef905d17253d40a2e1a4dbfc8296 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-63 |
| filingDate | 2018-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2bbea8535f5f72aef6b493a3328b16b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fac05669316effe24d3e388dfb9f027a |
| publicationDate | 2018-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2018202140-A1 |
| titleOfInvention | Positively charged water-soluble pro-drugs of ibuprofen |
| abstract | POSITIVELY CHARGED WATER-SOLUBLE PRO-DRUGS OF IBUPROFEN The novel positively charged pro-drugs of ibuprofen in the general formula (I) "Structure 1" were designed and synthesized. The compounds of the general formula (I) "Structure 1" indicated above can be prepared from functional derivatives of ibuprofen, (for example acid halides or mixed anhydrides), by reaction with suitable alcohols, thiols, or amines. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The experiment results suggest that the pro-drug, diethylaminoethyl 2-(p-isobutylphenyl) propionate.AcOH, diffuses through human skin -250 times faster than ibuprofen itself and -125 times faster than ethyl 2 -(p isobutylphenyl) propionate. In plasma, more than 90% of these pro-drugs can change back to the drug in a few minutes. The prodrugs can be used medicinally in treating any ibuprofen treatable conditions in humans or animals and be administered not only orally, but also transdermally for any kind of medical treatments and avoid most of the side effects of ibuprofen, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis. Controlled transdermal administration systems of the prodrug enables the ibuprofen to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of ibuprofen. |
| priorityDate | 2006-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.